Schizophrenia Pipeline

Jun 30, 2025

Schizophrenia, a term introduced over a century ago, continues to perplex clinicians and researchers alike. Characterized by hallucinations, delusions, disorganized thinking, and cognitive decline, it remains one of the most debilitating and misunderstood psychiatric conditions. Affecting approximately 20 million p...

Oct 18, 2024

Key Highlights  INVEGA and VRAYLAR (US)/REAGILA (EU) (cariprazine) accounted for the major share of the revenue market for schizophrenia patients in 2023. However, according to DelveInsight, this share is expected to decline by 2034 due to the launch of new emerging therapies. Schizophrenia has a robust...

Oct 18, 2024

Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this rate is 1 in 222 (0.45%). It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women. Schiz...

Sep 30, 2024

After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for t...